HCV Notes: NICE Nod To Gilead's <em>Epclusa</em>; Achillion, AbbVie Data Updates

HCV Notes: NICE Nod To Gilead's Epclusa; Achillion, AbbVie Data Updates

23 Sep 2016

The UK's health care cost-assessment body finds Gilead's newest combo, Epclusa, cost-effective in most HCV settings. J&J/Achillion now have 12-week SVR data for six-week treatment regimen, and AbbVie builds support for an eight-week regimen for Viekirax.

It's yet another win for Gilead Sciences Inc. in hepatitis C as the UK's National Institute for Health and Care Excellence (NICE) judges the specialty pharma's latest fixed-dose combination Epclusa (sofosbuvir/velpatasvir) cost-effective for just about all HCV-infected patients.

On Sept. 23, NICE recommended Epclusa as a treatment option for all six genotypes of HCV, with the caveat that it is not recommended for treatment-naïve, non-cirrhotic genotype 2 patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

26 May 2025

• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

20 May 2025

• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.